Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

FDAAA Impact Analysis (Year 4): The REMS Retreat Continues - For Now

May 29 2012

• By Michael McCaughan

Related Content

Two Indications, One REMS: FDA Panel Debates Restricted Access For <em>Truvada</em> In PrEP

May 21 2012

The Rebirth of A Niche Product: Three Silver Linings on the ESA REMS

Feb 01 2010

Regulatory Alchemy: The Transformative Power of the Opioid REMS

Jun 01 2011

FDAAA Impact Analysis (Year 3): REMS R.I.P.? Not Yet

Jun 01 2011

Transmucosal Fentanyl Products Become First Plug-and-Play REMS

Feb 01 2011

Setting the Stage: <em>Qnexa</em> and the Power of REMS

Mar 01 2012

REMS Use Declining, But Post-Marketing Requirements Remain

Nov 01 2011

Related Companies

Affymax, Inc.

Amgen, Inc.

Johnson & Johnson

Bristol Myers Squibb Company

Novo Nordisk A/S

Bayer AG

Vivus, Inc.

Gilead Sciences, Inc.

Corcept Therapeutics Incorporated

Roche Holding AG

Genentech, Inc.

Additional Topics

Post Market Regulation & Studies Risk Management BioPharmaceutical

More from Post-Marketing Regulation & Studies

More from Product Reviews

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window